Biotech Values

[DewDiligence]

SPRY/AQST—Aquestive will most likely benefit from [FDA approval for SPRY] as it will simplify the eventual approval of their product (sublingual epinephrine film).

It didn’t work out that way today—AQST closed down -21%. Investors presumably think SPRY and AQST are vying for an overlapping population of patients. I don’t follow either company, but the above premise seems sensible.